BLAINVILLE, QC, May 9, 2017 /CNW Telbec/ - Duchesnay is pleased to announce that Mictoryl® and Mictoryl® Pediatric (propiverine hydrochloride) are now available and ready for distribution in Canada for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB).1
Éric Gervais, Executive Vice President of Duchesnay, explains: "OAB is a medical condition that affects millions of Canadians each year, including children, and significantly impacts their quality of life. Duchesnay is pleased to offer a new therapeutic option, which is also indicated for pediatric use."
According to Dr. Jacques Corcos, urologist at the Jewish General Hospital and professor of Urology at McGill University, "Mictoryl is an interesting molecule approved for the adult and pediatric populations. Its dosage flexibility and its efficacy make it a credible alternative to other anticholinergics in OAB."
Jacqueline Cahill, Executive Director of the Canadian Continence Foundation, confirmed that "The Foundation is very pleased that a new therapeutic option is now available for patients suffering from overactive bladder, especially since it comes in both adult and pediatric formulations."
Overactive bladder consists of urinary urgency, usually accompanied by frequency and nocturia, which is defined as the need to wake up to urinate frequently during the night, with or without urge incontinence.2
Mictoryl® and Mictoryl® Pediatric are for adults and children who have difficulty in controlling their bladder due to bladder overactivity. Symptoms of bladder overactivity include the urgent need to urinate, needing to urinate more frequently or having the inability to hold one's urine.
Mictoryl is available in 30 mg and 45 mg modified-release capsules and is indicated in adults, including the geriatric population (>65 years of age).
Mictoryl Pediatric is available in 5 mg immediate release tablets and is indicated for body weight adjusted dosing in children from the age of 5 years with OAB up to a body weight of 35 kg. In children and adolescents with a body weight over 35 kg, the maximum recommended dose is 30 mg, administered in two daily doses.
Mictoryl® and Mictoryl® Pediatric were developed by the German pharmaceutical company, Apogepha, which specializes in the field of Urology. For more information about this medication, including contraindications, warnings, precautions, adverse reactions and dosing, please visit the Duchesnay website to access the product monograph and Consumer Information.
Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. Until recently, we focused on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding.
Today, Duchesnay has broadened its portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at different stages of their lives. To learn more about Duchesnay, visit duchesnay.com
1 Product Monograph, Mictoryl®/Mictoryl® Pediatric, Duchesnay Inc., Blainville, QC, Canada, December 30, 2016.
2 Abrams et al. 2002 The Standardisation of Terminology of Lower Urinary Tract Function. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. Joint publication: Neurourol.Urodyn 21(2):167-178 (2002 Wiley) Urology 61: 37-49, (2003 Elsevier)
SOURCE Duchesnay inc.
For further information: DUCHESNAY Inc., Ron Vaillancourt, Director of Communications, Duchesnay, 1 877 833-7734,email@example.com; Alida Alepian, Senior Consultant, Capital-Image, 514 739-1188, ext. 239, aalepian@capital-Image.com